Introduction: Chronic kidney disease (CKD) is a progressive condition characterized by the gradual loss of kidney function, often leading to systemic complications. Hematological abnormalities, including anemia, leukocytosis, and platelet dysfunction, are common in CKD and are linked to increased morbidity and mortality. This study aims to analyze hematological parameters in CKD patients and evaluate their association with disease severity. Objective: To investigate the hematological alterations, such as hemoglobin levels, leukocyte count, platelet count, mean platelet volume (MPV), and coagulation markers (prothrombin time [PT] and activated partial thromboplastin time [APTT]), in CKD patients and their correlation with disease stages. Methodology: A cross-sectional study was conducted over six months at the Pakistan Kidney Center, Abbottabad, involving 150 CKD patients aged 30–80 years. Blood samples were collected and analyzed for hemoglobin (Hb), total leukocyte count (TLC), platelet count, MPV, PT, and APTT. Patients with confounding conditions such as acute kidney injury, hematological malignancies, or recent blood transfusions were excluded. Data were analyzed using SPSS to assess associations between hematological parameters and CKD stages. Results: In our study, hemoglobin levels decreased progressively with CKD stages, ranging from 13.5 g/L in Stage 1 to 8.4 g/dL in Stage 5. Leukocyte counts increased with advancing CKD, from 6.5 ×10^9/L in Stage 1 to 9.2 ×10^9/L in Stage 5. Platelet count and MPV decreased with progression, with MPV rising from 8.1 fL in Stage 1 to 9.8 fL in Stage 5. Coagulation parameters (PT and APTT) were prolonged across all stages, with the longest values in Stage 5. Conclusion: Hematological abnormalities such as anemia, leukocytosis, and platelet dysfunction are prevalent in CKD and worsen with disease progression. These changes highlight the need for regular hematological monitoring in CKD management to prevent complications. Future studies should explore therapeutic interventions to address these hematological alterations and improve patient outcomes.